Five companies which can find a breakthrough solution for Alzheimer disease- ABT, LLY, JNJ, NVS, PFE
Northern, WI 03/13/2013 (avauncer) - There are five companies poised to find a breakthrough treatment for Alzheimer’s disease. They include the likes of Abbott Laboratories (NYSE:ABT), Eli Lilly & Co. (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Novartis AG – ADR (NYSE: NVS) and Pfizer Inc. (NYSE:PFE). Each of these companies is involved in research for Alzheimer’s disease that have shown some promise as a future solution.
Abbott Laboratories has a market cap around $55 billion. The Chicago-area based health care products company is conducting research in the area of neuroscience, developing compounds that target brain receptors regulating mood, memory and other functions of the brain. The company currently has 11 compounds in studies for various cognition related conditions including Alzheimer’s disease.
Eli Lilly & Co. is an Indianapolis, Indiana based pharmaceutical product company with a market cap of around $62 billion. The company’s experimental treatment, solanezumab, is part of a federally sponsored study being coordinated by Harvard Medical School. The study will be conducted over 3 years at a cost of $100 million.
Johnson & Johnson, the New Brunswick, New Jersey based healthcare research and development company, has a market cap around $214 billion. The company, in partnership with Pfizer Inc., has developed bapineuzumab designed to change the course of Alzheimer’s disease. The drug is showing some results in the reduction of certain signs associated with Alzheimer’s disease.
Swedish based healthcare solutions company Novartis AG – ADR market cap is around $168 billion. The company’s Exelon Patch (known as rivastigmine transdermal system) used with people that have mild to moderate Alzheimer’s disease has been approved by the U.S. Food and Drug Administration to administer higher doses of the drug to patients.
Finally Pfizer Inc., with a market capitalization of around $201 billion is a New York City based research and biopharmaceutical company. Along with Johnson & Johnson, its bapineuzumab, has shown promise in reducing physical damage in the brain and reduced the buildup of amyloid plaque, which is associated with Alzheimer’s disease.
Shares of Abbott Laboratories (NYSE:ABT) were up by 0.14% to close at $34.98. Shares of Eli Lilly & Co. (NYSE:LLY) were up by 0.02% to close at $55.08. Shares of Johnson & Johnson (NYSE:JNJ) were up by 0.15% to close at $78.56. Shares of Novartis AG - ADR (NYSE:NVS) were up by 0.78% to close at $69.53. Shares of Pfizer Inc. (NYSE:PFE) were down by 1.1% to close at $27.94.